Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

checkorphan
Learn more about:
Hyperprolactinemia
Related Clinical Trial
Administration of Kisspeptin to Subjects With Reproductive Disorders The Luveris In Vitro Fertilization Trial A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Pituitary Function and Spontaneous Intracranial Hypotension Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility Aripiprazole and Prolactin Study Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Characterization of Macroprolactinemia Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Endometriosis Patients Undergoing Quinagolide Treatment Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Hyperprolactinemia and Adrenal Steroidogenesis Administration of Kisspeptin in Patients With Hyperprolactinemia Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Brief Title

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Official Title

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability

Brief Summary

      The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist
      ropinirole for the treatment of hyperprolactinemia in patients with idiopathic
      hyperprolactinemia and prolactinomas.

Detailed Description

      Treatment of prolactin secreting pituitary tumors with traditional ergot dopamine agonist
      drugs can be limited by medication side effects, pharmacologic resistance, and by concerns
      regarding the potential risk of cardiac valve disease. The overall goal of this project is
      therefore to evaluate, for the first time, the efficacy and tolerability of the selective
      D2/D3 receptor non-ergot dopamine agonist ropinirole for the treatment of prolactinomas. This
      proposal will establish the pharmacologic profile of this medication when used to treat
      hyperprolactinemia in patients with prolactinomas and will determine the impact of long-term
      ropinirole administration on critical clinical parameters including serum prolactin levels,
      gonadal function, and tumor regression, in order to establish ropinirole's utility as a new,
      clinically efficacious, safer and more tolerable therapeutic option for the treatment of
      prolactinomas that may prove particularly useful in patients with underlying cardiac valve
      disease and in those with resistance or intolerance to ergot dopamine agonists.

Study Phase

Phase 1/Phase 2

Study Type

Interventional

Primary Outcome

Percentage of Subjects That Achieved Stable PRL Normalization

Secondary Outcome

 Number of Subjects With Unchanged Tumor Size

Condition

Hyperprolactinemia

Intervention

Ropinirole

Study Arms / Comparison Groups

 ROP Intervention
Description:  Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

16

Start Date

September 16, 2016

Completion Date

November 5, 2020

Primary Completion Date

November 5, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Ages 18-70 years

          -  Prolactin level (PRL) ≥2 times upper limit of normal

          -  Pituitary adenomas on MRI ≤ 1.5cm in greatest diameter and ≥ 5mm from the optic chiasm

          -  Normal renal and liver function

          -  Agrees to barrier contraception if pre-menopausal

        Exclusion Criteria:

          -  Use of medications known to interfere with PRL secretion and PRL and Ropinirole (ROP)
             metabolism

          -  Use of another dopamine agonist during the 4 weeks prior

          -  Pituitary stalk compression on MRI

          -  History of visual field abnormalities or previous radiation

          -  Untreated hypothyroidism

          -  Consumption of > 2 alcoholic drinks per day

          -  Pregnancy

Gender

All

Ages

18 Years - 70 Years

Accepts Healthy Volunteers

No

Contacts

Gabrielle Page-Wilson, M.D., ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT03038308

Organization ID

AAAI8604

Secondary IDs

1R21DK112093-01

Responsible Party

Sponsor

Study Sponsor

Columbia University

Collaborators

 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Sponsor

Gabrielle Page-Wilson, M.D., Principal Investigator, Columbia University

Verification Date

July 2021